Takeda can't avoid evidence in US antitrust case over Amitiza, plaintiffs say
( May 4, 2026, 20:49 GMT | Official Statement) -- MLex Summary: End-payor plaintiffs opposed judgment in favor of Takeda Pharmaceuticals in a US case accusing it of illegally delaying generic competition to its brand name drug Amitiza. They argued that all of the evidence, when viewed in the light most favorable to the purchasers, confirms that a reasonable jury could find in favor of the purchasers.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.